Figure 4.

Comparison of the spectrum of key mutations before and after the first-line therapy. The left three lanes (baseline group) and the right three lanes (after first line group) indicate the high-frequency mutational status for baseline (before the first-line therapy) and after the first-line therapy. Annotations to the right of the panel show the exact mutations and the percentage to the left of the panel shows the frequency for a certain mutation. The three lanes in both group illustrates the mutational status for PD, PR, and SD groups, respectively. Blue squares indicates cases with bevacizumab/chemotherapy that carried corresponding labeled mutations and red squares indicates cases with cetuximab/chemotherapy that carried corresponding labeled mutations.